These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 30271319)

  • 1. HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction.
    Paudel YN; Shaikh MF; Chakraborti A; Kumari Y; Aledo-Serrano Á; Aleksovska K; Alvim MKM; Othman I
    Front Neurosci; 2018; 12():628. PubMed ID: 30271319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGB1-Mediated Neuroinflammatory Responses in Brain Injuries: Potential Mechanisms and Therapeutic Opportunities.
    Paudel YN; Angelopoulou E; Piperi C; Othman I; Shaikh MF
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32610502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-κB pathway following experimental traumatic brain injury.
    Chen X; Wu S; Chen C; Xie B; Fang Z; Hu W; Chen J; Fu H; He H
    J Neuroinflammation; 2017 Jul; 14(1):143. PubMed ID: 28738820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy.
    Ravizza T; Terrone G; Salamone A; Frigerio F; Balosso S; Antoine DJ; Vezzani A
    Brain Behav Immun; 2018 Aug; 72():14-21. PubMed ID: 29031614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurogenesis after traumatic brain injury - The complex role of HMGB1 and neuroinflammation.
    Manivannan S; Marei O; Elalfy O; Zaben M
    Neuropharmacology; 2021 Feb; 183():108400. PubMed ID: 33189765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High mobility group box 1 (HMGB1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches.
    Paudel YN; Semple BD; Jones NC; Othman I; Shaikh MF
    J Neurochem; 2019 Dec; 151(5):542-557. PubMed ID: 30644560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glycyrrhizin on traumatic brain injury in rats and its mechanism.
    Gu XJ; Xu J; Ma BY; Chen G; Gu PY; Wei D; Hu WX
    Chin J Traumatol; 2014; 17(1):1-7. PubMed ID: 24506915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-mobility group box 1 inhibits HCO(3)(-) absorption in medullary thick ascending limb through a basolateral receptor for advanced glycation end products pathway.
    Good DW; George T; Watts BA
    Am J Physiol Renal Physiol; 2015 Oct; 309(8):F720-30. PubMed ID: 26180239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative impairment of cognitive function in old mice: a possible role for neuroinflammation mediated by HMGB1, S100B, and RAGE.
    Li RL; Zhang ZZ; Peng M; Wu Y; Zhang JJ; Wang CY; Wang YL
    J Surg Res; 2013 Dec; 185(2):815-24. PubMed ID: 23899512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures.
    Iori V; Maroso M; Rizzi M; Iyer AM; Vertemara R; Carli M; Agresti A; Antonelli A; Bianchi ME; Aronica E; Ravizza T; Vezzani A
    Neurobiol Dis; 2013 Oct; 58():102-14. PubMed ID: 23523633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target.
    Mao D; Zheng Y; Xu F; Han X; Zhao H
    Front Neurol; 2022; 13():1029891. PubMed ID: 36388178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation.
    Ullah MA; Loh Z; Gan WJ; Zhang V; Yang H; Li JH; Yamamoto Y; Schmidt AM; Armour CL; Hughes JM; Phipps S; Sukkar MB
    J Allergy Clin Immunol; 2014 Aug; 134(2):440-50. PubMed ID: 24506934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy.
    Wang S; Guan Y; Li T
    Curr Drug Targets; 2021; 22(2):171-182. PubMed ID: 32729417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting high-mobility group box protein 1 (HMGB1) in pediatric traumatic brain injury: Chronic neuroinflammatory, behavioral, and epileptogenic consequences.
    Webster KM; Shultz SR; Ozturk E; Dill LK; Sun M; Casillas-Espinosa P; Jones NC; Crack PJ; O'Brien TJ; Semple BD
    Exp Neurol; 2019 Oct; 320():112979. PubMed ID: 31229637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGB1-RAGE Signaling Plays a Role in Organic Dust-Induced Microglial Activation and Neuroinflammation.
    Massey N; Puttachary S; Bhat SM; Kanthasamy AG; Charavaryamath C
    Toxicol Sci; 2019 Jun; 169(2):579-592. PubMed ID: 30859215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury.
    Gao TL; Yuan XT; Yang D; Dai HL; Wang WJ; Peng X; Shao HJ; Jin ZF; Fu ZJ
    J Trauma Acute Care Surg; 2012 Mar; 72(3):643-9. PubMed ID: 22491548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentration of high-mobility group box 1, Toll-like receptor 4 as biomarker in epileptic patients.
    Yue Z; Tang J; Peng S; Cai X; Rong X; Yang L
    Epilepsy Res; 2023 May; 192():107138. PubMed ID: 37075527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue.
    Casula M; Iyer AM; Spliet WG; Anink JJ; Steentjes K; Sta M; Troost D; Aronica E
    Neuroscience; 2011 Apr; 179():233-43. PubMed ID: 21303685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
    van Beijnum JR; Buurman WA; Griffioen AW
    Angiogenesis; 2008; 11(1):91-9. PubMed ID: 18264787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-high mobility group box protein 1 monoclonal antibody downregulating P-glycoprotein as novel epilepsy therapeutics.
    de Liyis BG; Tandy SG; Endira JF; Putri KA; Utami DKI
    Egypt J Neurol Psychiatr Neurosurg; 2022; 58(1):121. PubMed ID: 36310854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.